Search
Lutetium Lu177 Edotreotide
go.drugbank.com/drugs/DB17278InvestigationalCategories: Compounds used in a research, industrial, or household settingAOD9604
go.drugbank.com/drugs/DB06388ExperimentalAOD9604 is a synthetic analogue of the lipolytic domain of human growth hormone, being investigated for the treatment of obesity.
DP-b99
go.drugbank.com/drugs/DB05820InvestigationalDP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment
Calanolide A
go.drugbank.com/drugs/DB04886InvestigationalCalanolide A is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) derived from a plant found in the Malaysian rain forest. A related compound, calanolide B, also has anti-HIV activity. … A preliminary dosing study among HIV-infected individuals showed a significant antiviral effect compared with placebo.
Pipendoxifene
go.drugbank.com/drugs/DB05414InvestigationalER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer. … Pipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and was selected for further development as a treatment
Bradanicline
go.drugbank.com/drugs/DB06090InvestigationalBradanicline, a novel small molecule that modulates the activity of the neuronal nicotinic receptor (NNR) subtype known as alpha7(α7). Bradanicline belongs to a new class of drugs for the treatment of central nervous system diseases and ...
ISF402
go.drugbank.com/drugs/DB06315ExperimentalISF402 is an investigational peptide tetramer which helps dispersal of insulin via zinc chelation, therefore allowing insulin hexamers to break free.
Oxantel
go.drugbank.com/drugs/DB13670InvestigationalOxantel is an anthelmintic drug that targets parasitic acetylcholine receptors.[A275093, A275098]
LX6171
go.drugbank.com/drugs/DB05180InvestigationalLX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia